Where pursuant to Article 17(4) of Regulation (EU) 2021/2282, the Coordination Group, via the HTA secretariat, informs the health technology developer that it will engage in the joint scientific consultation on medicinal products, it should also inform the health technology developer of the timetable for the joint scientific consultation, including the deadline to submit the briefing package. To ensure that joint scientific consultations on medicinal products that are conducted in parallel with the scientific advice have synchronised timing, the timetable should be synchronised with the scientific advice process.
Recital 8, Regulation (EU) 2024/3169
In forcesince 18 Dec 2024